SecBot SecBot
6-K ·Filed Aug 12, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-345702
Notable filing: 6-K
Actionable Insight • Neutral

The binary event is the CHAPTER-3 topline data expected within the next ~6 weeks. A positive readout would validate the XR prophylaxis program and significantly de-risk the pipeline, while a negative or mixed result would be a major setback. Traders should position for high volatility around the data release, with the PDUFA date in April 2027 providing a longer-term catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

deucrictibant

◆ Mixed Named in this 6-K
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$36.46
T+0 close · Aug 12, 2026 · via day close
Latest settled
−5.84%
T+60 · $34.33
Vs SPY
−0.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $36.46entry
  2. T+1 · 3mo ago −6.64%α −7.34% · $34.04
  3. T+5 · 3mo ago −0.52%α −0.08% · $36.27
  4. T+20 · 2mo ago +2.88%α +4.78% · $37.51
  5. T+60 · 12d ago −5.84%α −0.97% · $34.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris reported Q2 2026 financial results with no revenue, a net loss of €47.8M (€0.70/share), and cash of €318M. The key catalyst is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, alongside the ongoing FDA review of the deucrictibant IR NDA with a PDUFA date of April 23, 2027. The May 2026 $132M offering extends the cash runway into 2028, funding pre-commercial activities and lifecycle management, but the pre-revenue stage and increasing operating losses keep the stock binary on pipeline execution.

Key Facts

  • No revenue generated for Q2 2026 or Q2 2025.
  • Net loss of €47.8M for Q2 2026 vs €45.5M for Q2 2025.
  • Cash and cash equivalents of €318M as of June 30, 2026, up from €292M at Dec 31, 2025.
  • Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026.
  • Deucrictibant IR NDA under FDA review with PDUFA date of April 23, 2027; MAA validated by EMA in July 2026.
  • Closed a $132.3M underwritten offering in May 2026, extending cash runway into 2028.
  • R&D expenses increased 18% YoY to €35.0M; G&A expenses increased 47% YoY to €15.8M.
  • Enrollment ongoing in CREAATE, a pivotal Phase 3 study for AAE-C1INH.

Financial Impact

Net loss of €47.8M in Q2 2026, with cash burn of €86.6M in operating activities for H1 2026. Cash runway extended into 2028 via $132.3M May 2026 offering.

cashnet lossoperating expenses

Risk Factors

  • CHAPTER-3 Phase 3 data may fail to meet primary or key secondary endpoints.
  • FDA may not approve deucrictibant IR NDA by the PDUFA date or at all.
  • Increasing operating losses and cash burn rate may require additional dilutive financing before reaching profitability.
  • Competition from existing HAE therapies (e.g., Takhzyro, Orladeyo) could limit commercial uptake if approved.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-345702
Document: phvs-ex99_2.htm0001193125-26-345702
Document: phvs-20260630.htm0001193125-26-345702
Document: phvs-ex99_1.htm0001193125-26-345702
Document: 0001193125-26-345702-index-headers.html0001193125-26-345702
Document: 0001193125-26-345702-index.html0001193125-26-345702
Document: 0001193125-26-345702.txt0001193125-26-345702

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026